0001801385-23-000004.txt : 20230523
0001801385-23-000004.hdr.sgml : 20230523
20230523162320
ACCESSION NUMBER: 0001801385-23-000004
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230519
FILED AS OF DATE: 20230523
DATE AS OF CHANGE: 20230523
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Romano Kathryn
CENTRAL INDEX KEY: 0001801385
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38210
FILM NUMBER: 23949174
MAIL ADDRESS:
STREET 1: C/O KRYSTAL BIOTECH, INC.
STREET 2: 2100 WHARTON STREET, SUITE 701
CITY: PITTSBURGH
STATE: PA
ZIP: 15203
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Krystal Biotech, Inc.
CENTRAL INDEX KEY: 0001711279
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 821080209
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2100 WHARTON STREET
STREET 2: SUITE 701
CITY: PITTSBURGH
STATE: PA
ZIP: 15203
BUSINESS PHONE: (412) 586-5830
MAIL ADDRESS:
STREET 1: 2100 WHARTON STREET
STREET 2: SUITE 701
CITY: PITTSBURGH
STATE: PA
ZIP: 15203
4
1
wf-form4_168487338437565.xml
FORM 4
X0407
4
2023-05-19
0
0001711279
Krystal Biotech, Inc.
KRYS
0001801385
Romano Kathryn
C/O KRYSTAL BIOTECH, INC.
2100 WHARTON STREET, SUITE 701
PITTSBURGH
PA
15203
0
1
0
0
Chief Accounting Officer
1
Common Stock
2023-05-19
4
M
0
12500
52.26
A
28484
D
Common Stock
2023-05-19
4
S
0
12500
95.05
D
15984
D
Common Stock
2023-05-19
4
M
0
12500
52.26
A
28484
D
Common Stock
2023-05-19
4
S
0
12500
95.0449
D
15984
D
Common Stock
2023-05-19
4
S
0
3428
95.0808
D
12556
D
Common Stock
2023-05-22
4
M
0
2521
52.26
A
15077
D
Common Stock
2023-05-22
4
S
0
2521
105.8036
D
12556
D
Common Stock
2023-05-22
4
M
0
2570
52.26
A
15126
D
Common Stock
2023-05-22
4
S
0
2570
106.8087
D
12556
D
Common Stock
2023-05-22
4
M
0
1300
52.26
A
13856
D
Common Stock
2023-05-22
4
S
0
1300
107.8777
D
12556
D
Common Stock
2023-05-22
4
M
0
2955
52.26
A
15511
D
Common Stock
2023-05-22
4
S
0
2955
109.1719
D
12556
D
Common Stock
2023-05-22
4
M
0
3154
52.26
A
15710
D
Common Stock
2023-05-22
4
S
0
3154
109.9933
D
12556
D
Common Stock
2023-05-22
4
M
0
12500
63.55
A
25056
D
Common Stock
2023-05-22
4
S
0
12500
110
D
12556
D
Stock Option (Right to Buy)
52.26
2023-05-19
2023-05-19
4
M
0
12500
0
D
2030-01-30
Common Stock
12500.0
37500
D
Stock Option (Right to Buy)
52.26
2023-05-19
2023-05-19
4
M
0
12500
0
D
2030-01-30
Common Stock
12500.0
25000
D
Stock Option (Right to Buy)
52.26
2023-05-22
2023-05-22
4
M
0
12500
0
D
2030-01-30
Common Stock
12500.0
12500
D
Stock Option (Right to Buy)
63.55
2023-05-22
2023-05-22
4
M
0
12500
0
D
2032-02-27
Common Stock
12500.0
37500
D
The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $95.00 per share.
The transaction was executed in multiple trades ranging from $95.0000 to $95.3800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates sales of 3,428 shares with a limit price of $95.00 per share.
The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $105.00 per share.
The transaction was executed in multiple trades ranging from $105.3400 to $106.3100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $106.3700 to $107.0300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $107.6900 to $108.4200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $108.9000 to $109.5500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $109.9700 to $110.0000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $110.00 per share.
The transaction was executed in a single trade.
50,000 options were granted that vest in four equal annual installments beginning on January 21, 2021.
50,000 options were granted that vest in four equal annual installments beginning on February 28, 2023.
/s/ Kathryn Romano
2023-05-23